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PDA Closure in ELBW Infants: If, 
When, and How to Do It
Stephanie Whiting and Shyam Sathanandam
Abstract
Patent ductus arteriosus (PDA) is the most common cardiovascular condition 
afflicting premature neonates especially those born extremely low birth weight 
(ELBW). Despite five decades of scientific inquiry which has produced thousands of 
publications including over 65 randomized controlled trials, cardiologists, neona-
tologists, and surgeons still cannot answer simple questions such as if, when and how 
to close to the PDA in ELBW infants. This chapter will examine current evidence in 
order to answer these fundamental questions. The chapter will specifically focus on 
transcatheter PDA closure (TCPC), which albeit a new therapy, has displayed great 
potential to be the best therapeutic option in the future. It is about time that physi-
cians from all sub-specialties come together and integrate the evidence to develop a 
management algorithm for ELBW infants with hemodynamically significant PDA.
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1. Introduction
The ductus arteriosus is a fetal vascular structure that connects the descending 
aorta to the pulmonary artery (PA). It develops from the left sixth aortic arch in the 
embryo by the sixth week, directing blood flow returning to the heart away from 
the lungs. Soon after birth, the ductus arteriosus should begin to close spontane-
ously in response to environmental changes [1]. Patent ductus arteriosus (PDA) 
can be expected in all infants immediately after birth but may become pathologic if 
closure fails to occur within the first few days. Non-pathologic PDAs may occur in 
infants with cyanotic heart disease and increased pulmonary vascular resistance.
2. Role in fetal life
In a normal fetus, blood flows from right-to-left (PA to aorta) as a result of high 
resistance in the pulmonary arterioles and low systemic vascular resistance in the 
fetus and placenta. Patency of the ductus in fetal life is further influenced by oxy-
gen content in the blood and prostaglandins. Dissolved oxygen content in the blood 
(pO2) leads to constriction of smooth-walled vessels, possibly due to the influx of 
calcium into the cell, thus ductal exposure to low pO2 in utero promotes patency 
of the ductus [2]. Prostaglandins are hormone-like compounds derived from 
arachidonic acid by cyclooxygenase enzymes (COX-1 and COX-2). Prostaglandin E 
(PGE) and prostacyclin (PGIE) are produced in the ductus and play a large role in 
maintaining its patency during fetal life [2–5].
Update on Critical Issues on Infant and Neonatal Care
2
3. Normal closure of the ductus
When a baby takes its first breath, the increased alveolar oxygen content leads 
to pulmonary vasodilation, resulting in a decreased ratio of pulmonary vascular 
resistance (RP) to systemic vascular resistance (RS). This drop in RP/RS can reverse 
the flow of blood across the ductus arteriosus from right-to-left to left-to-right 
(aorta to PA). At this point, the ductus is exposed to high systemic arterial pO2, 
which results in vasoconstriction of the ductus arteriosus through mechanisms not 
fully elucidated [3–5]. A sharp decline in circulating PGE and PGIE along with a 
rapid increase in pO2 following birth contributes to constriction, and ultimately 
functional closure of the ductus. Nearly all healthy, term infants achieve functional 
closure with 24–72 h [2–5]. Eventually, hypoxia and fibrosis cause the inner layers of 
the ductus to permanently close, leaving only a fibrous remnant called the ligamen-
tum arteriosum.
4. Incidence of PDA in premature infants
Premature birth prolongs closure as gestational age decreases. As many as 
50–70% of infants at <28 weeks of gestation have a moderate-to-large PDA that 
persists for weeks after birth, whereas most infants born >28 weeks of gestation 
spontaneously close the ductus within the first week. Among infants >1500 g, 
spontaneous closure of the ductus occurs within 96 h in 95% of neonates [6]. 
By contrast, only 34% of extremely low birth weight (ELBW) infants (birth 
weight ≤ 1000 g) are reported to close the ductus by day 10 of life [6].
Little is known about the natural course of PDA in extremely premature infants 
due to the use of prophylactic and rescue therapy in modern NICUs. Previous 
studies in the 1960s and 1970s were limited by a lack of modern imaging tech-
niques and likely only captured audible, hemodynamically significant PDAs [7]. 
The closest approximation is found by examining infants treated with conserva-
tive management of the PDA, in which interventions are held until symptoms of 
distress meet an established threshold. A large retrospective study using conserva-
tive management found that 85% of very low birth weight (VLBW) infants (birth 
weight ≤ 1500 g) closed the ductus spontaneously before discharge, but it should 
be noted that infants <26 weeks gestational age took a median of 71 days to close. 
Thirty-three infants, many of whom had a PDA, were excluded from the study due 
to death from infection, intraventricular hemorrhage (IVH), necrotizing entero-
colitis (NEC), and pulmonary hemorrhage [8] (Semberova). Another study found 
spontaneous ductal closure within the first week in 31% of ELBW infants and 67% 
in infants greater than 1000 g. For ELBW infants, spontaneous closure was achieved 
in 47% at a median of 56 days at the time of discharge [8, 9]. Thus, PDA in VLBW 
and ELBW infants can take weeks to close and may cause morbidity and mortality 
in this population.
5. Consequences of PDA in ELBW infants
While a very tiny ductus may be safely left untreated, a large ductus can cause 
pulmonary over-circulation and cardiac failure. A moderate ductus can lead to 
pulmonary hypertension [10, 11] in the long-term. Even a small ductus is at risk for 
developing endocarditis [12].
Persistent PDA in ELBW infants with respiratory distress syndrome (RDS) 
has been linked to numerous pulmonary complications, including increased flow 
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and pressure to the pulmonary vascular bed, increased lung water, decreased lung 
compliance [13, 14], prolonged ventilation [15], worsening pulmonary disease [16], 
pulmonary hemorrhage [13–16], severe bronchopulmonary dysplasia (BPD) [17], 
and death [17].
Over the first few days, pulmonary vascular resistance drops markedly while 
the PDA remains large, allowing significant shunting of blood to the pulmonary 
vascular bed. As blood from the PDA returns to the left atrium, left atrial dila-
tion occurs. The increased LA pressure causes pulmonary edema and symptoms 
of congestive heart failure. While the body may compensate at first, pulmonary 
hemorrhage may eventually occur [18, 19]. Besides pulmonary hemorrhage the risks 
of BPD are increased, as ELBW infants require greater ventilatory support as well as 
increased oxygen [18, 20]. Although the pathogenesis of BPD is complex, associa-
tions between prolonged exposure to a moderate-to-large PDA and BPD have been 
documented [18, 19]. Additional research further established the association of 
PDA with systemic complications such as NEC, renal impairment, IVH, periven-
tricular leukomalacia (PVL), cerebral palsy, and death [20–22].
While numerous sequelae have been associated with the presence of a moderate-
to-large PDA in ELBW infants, it remains unclear whether these are the result of 
having a PDA or are the natural consequences of prematurity. Previous randomized 
control trials (RCT) suggest that long-term morbidities are not affected by short-
term exposure to a PDA (3–4 days) [13, 23], however these conclusions are con-
founded by early spontaneous closure of the PDA, failure to account for differing 
shunt sizes, and the early use of rescue treatments, or a lack of equipoise, on behalf 
of the physicians [13]. There is no consensus on the exact consequences of a PDA 
in the premature infant, but most agree that persistent and significant left-to-right 
shunting of blood in the ELBW infant is not helpful [24].
6. Hemodynamic significance of the PDA
There is no consensus regarding the definition of a hemodynamically significant 
PDA (hsPDA), yet it is a key indicator for clinicians when determining whether inter-
vention is needed to close the ductus. Historically, clinical signs have been used as 
indicators of hsPDA, such as the presence of a systolic murmur, wide pulse pressures, 
Figure 1. 
Transthoracic echocardiogram (TTE) demonstrating a large, hsPDA in a 3 weeks old ex-24 week ELBW 
infant. (A) 2D-TTE demonstrating a large PDA between the aorta and the pulmonary artery (PA). (B) Color 
Doppler demonstrating left to right shunt in the PDA from the aorta to the PA. (C) Severe left atrial (LA) and 
left ventricular (LV) enlargement relative to the right atrium (RA) and the right ventricle (RV).
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bounding pulses, pulmonary edema, and increased oxygen requirements. With the 
advent of echocardiography in the 1970s, more sophisticated measures can be used to 
determine hemodynamic significance. Approaches to determine hsPDA now include 
(1) establishing thresholds based on clinical signs and echocardiographic parameters, 
(2) the need for treatment as determined by the size of the PDA and its likelihood of 
closing based on age/size of the infant, (3) probable outcomes based on identifying 
populations most likely to experience complications related to PDA.
Echocardiographic indices to determine hsPDA can be established by PDA shunt 
size, the extent of volume overload [19–21], the degree of pulmonary overload, and 
the magnitude of systemic hypoperfusion (Figure 1). Moderate to large PDAs may 
be hemodynamically significant if flow patterns through the duct indicate signifi-
cant left-to-right shunting. Volume overload is determined by calculating the left 
atrium diameter (LA) relative to a constant, the aortic root diameter (Ao). An LA:Ao 
ratio greater than 1.4 is one of the most commonly used indicators of hsPDA, since 
increased volume through the PDA will return to the left atrium and cause dilation 
[19–21]. Left ventricular output (LVO), a key indicator of pulmonary overload, may 
be large due to additional volume from the PDA, or may be small to normal (an omi-
nous sign) if the left ventricle fails to compensate for the additional volume through 
Clinical criteria Echocardiographic criteria
• Oxygenation difficulty (oxygenation index ≥ 10) • PDA diameter ≥ 2 mm
• High ventilator settings (Mean airway 
pressure ≥ 10)
• Absent diastolic flow or reversal of end-
diastolic flow in descending aorta, superior 
mesenteric, middle cerebral or renal artery
• Frequent episodes of oxygen desaturations, apnea or 
bradycardia
• Unrestrictive pulsatile transductal flow
• Inability to feed/abdominal distention • Left heart enlargement (LA:Ao ratio ≥1.4)
• Systemic hypotension (low mean or diastolic BP)
• Cardiomegaly ± Pulmonary edema on chest X-ray
• Metabolic acidosis
Table 1. 
Clinical and echocardiographic criteria for hemodynamic significance.
Figure 2. 
Pulse wave Doppler assessment in the descending aorta by TTE in the same patient in Figure 1. (A) There is 
diastolic flow reversal in the descending aorta (arrows) suggesting a large left to right shunt from the aorta to 
the PA leading to systemic hypoperfusion. (B) Following transcatheter closure, there is normalization in the 
Doppler pattern.
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increased cardiac output. Another indicator of pulmonary overload is the end-
diastolic velocity in the PA, where high velocities may indicate pulmonary overload. 
Retrograde diastolic blood flow through the descending aorta (Figure 2) may be the 
most telling sign of systemic hypoperfusion due to a PDA, although end-organ blood 
flow may be assessed to further quantify these effects [19–21].
Echocardiographic evidence alone cannot determine hsPDA, but should be used 
in conjunction with clinical factors (Table 1), vulnerability of the infant due to ges-
tational and chronological age, and risk of organ overflow (lungs) or hypoperfusion 
(brain, kidneys, intestines). Clinical findings that may help identify hsPDA include 
the need for vasopressors/inotropes, ventilator support and pulmonary edema, 
feeding intolerance, and rising creatinine levels.
7. Established techniques for closure
Treatment options are continuously evolving [25], and have included routine 
pharmacological treatment, conservative management, surgical ligation and trans-
catheter closure (Table 2). While indications for closure are not fully agreed upon, 
certain contraindications are noted below:
• Severe pulmonary vascular disease.
• Pulmonary artery hypoplasia.
• Duct dependent congenital heart disease
7.1 Medical therapy
Pharmacological treatment with COX inhibitors is usually the initial treat-
ment for PDA. Currently, pharmacological therapy consists of intravenous or oral 
Pharmacologic therapy Surgical ligation Transcatheter closure
Advantages:
• Non-Invasive
• Efficacy 50–70%
• May take a few days to be 
effective
Advantages:
• Invasive
• Efficacy 100%
• Immediate and definitive
closure
Advantages:
• Minimally-Invasive
• Efficacy 100%
• Immediate and definitive closure
Disadvantages:
• Impairment in renal func-
tion, oliguria, proteinuria, 
hyperkalemia
• Cerebral white-matter 
damage
• Impairment in cerebral 
perfusion
• NEC, Gastrointestinal 
perforation
• Platelet dysfunction
Disadvantages:
• Post-Ligation Syndrome (30%)
• Vocal cord dysfunction (30%)
• Impaired neurodevelopmental 
outcomes
• Risk of worsening of BPD
• Chylothorax
• Diaphragmatic paralysis
• Bleeding
• Pneumothorax
• Cardiorespiratory failure
Disadvantages:
• Vascular access complications 
(1%)
• LPA stenosis (1%)
• Aortic arch stenosis (1%)
• Device embolization (1%)
• Tricuspid valve regurgitation 
(2%)
• Exposure to X-Rays and contrast 
medium
• Hypothermia
Table 2. 
Advantages and disadvantages of therapies.
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indomethacin, ibuprofen, or acetaminophen in varying dosages. The two most 
common options are intravenous standard doses of indomethacin and ibuprofen. 
In 2018, a meta-analysis of 68 RCT of 4802 infants found that among all preterm 
infants <37 weeks gestation, the overall PDA closure rate with one of the above 
treatment modalities was 67%. Oral ibuprofen was the most effective treat-
ment, and none of the treatments increased the risk of mortality, NEC, or IVH 
compared to placebo or no treatment controls [25]. Slower absorption rates and a 
longer half-life of oral ibuprofen may increase the time of contact with the PDA, 
possibly explaining its improved effectiveness over intravenous routes [25]. The 
effectiveness of medical therapy is at best 50–70% and lower for those <32 weeks 
gestation [24–26].
Conservative management without the use of pharmacotherapeutics has become 
a recent trend in management of the PDA [16, 22]. Because many preterm infants 
will spontaneously close the ductus within the first week, early routine treatment 
with pharmacological therapy may not offer any benefit. Targeted therapy towards 
hsPDA based on clinical and echocardiographic thresholds is becoming the stan-
dard of care.
7.2 Surgical ligation
Surgical ligation through a limited left thoracotomy, although invasive, offers 
definitive, immediate closure of the PDA. Robert Gross performed the first 
successful PDA surgical ligation at Children’s Hospital of Boston in 1939 while his 
chief was out of town. While surgical ligation carries minimal risk of mortality, 
other risks include pneumothorax, recurrent laryngeal nerve paralysis, chylous 
effusions, and post-ligation syndrome [12, 24, 26, 27]. Post-ligation syndrome 
occurs in the first 6–24 h in approximately 30% of neonates who undergo surgical 
ligation; neonates experience hypotension, which in some cases may be resistant 
to catecholamines, as a result of changes in myocardial function and impaired 
vascular tone [20, 21]. Long term complications such as thoracic scoliosis and 
neurosensory impairment have been reported in some cases following surgical 
ligation [24, 26, 27]. Only one trial has compared surgical ligation to noninter-
vention and found that infants undergoing ligation required longer ventilation, 
oxygen therapy, and hospitalization than control subjects, although differences 
did not reach statistical significance [28]. Even so, surgical ligation may still be 
desirable in infants for whom medical therapy has failed and transcatheter closure 
is not possible [12].
7.3 Transcatheter therapy
Transcatheter PDA closure (TCPC) is a minimally invasive therapy associ-
ated with low rate of adverse events that has become the procedure of choice for 
children >5 kg [29]. Historically, transcatheter closure of PDA has not been per-
formed in premature neonates for a variety of reasons including: fear of patient 
fragility, concerns regarding vascular access and arterial injury, unknown effects 
of intravenous contrast media, concerns regarding catheter manipulation, and 
most importantly, absence of a suitable PDA closure device. Recently, a growing 
body of clinical evidence has emerged suggesting that transcatheter closure of 
PDA can be performed safely and effectively in premature infants [24, 30]. Risks 
of transcatheter therapy include embolization requiring surgery, cardiac perfora-
tion, aortic coarctation, and LPA obstruction, however these risks are very low 
even among ELBW infants.
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8. Highlights of transcatheter PDA closure
• No arterial access is needed for the procedure.
• The procedure time is minimal.
• Therapy is definitive and minimally-invasive.
• Risks of pharmacotherapeutics and surgery can be avoided.
• The procedure can be safely performed in infants as small as 700 g using an 
FDA-approved device.
9. Controversy and practice variation
Controversy regarding if, when, and how to close the PDA abounds. Survey 
results of neonatologists and cardiologists in 2018 describe the practice variations 
in management of the PDA [31]. Some neonatologists responded that even a large, 
hemodynamically significant PDA in a premature baby never requires treatment 
including medical management as the majority are likely to close, while no cardiolo-
gists agree with this option. Nearly half the neonatologists believe that closing the 
PDA does not alter outcomes in children born <28 weeks’ gestation, while most 
of the cardiologists disagree with this opinion. When institutions do believe that 
closure is needed after failed medical therapy, the majority of neonatologists and 
cardiologists currently still prefer surgical ligation to TCPC, while watchful wait-
ing was still preferred by some neonatologists. There are immense variations in the 
practice of managing PDAs in ELBW infants in the United States. Neonatologists 
and cardiologists have differing opinions of the consequence of a hsPDA on the 
eventual outcomes. Certain landmark papers questioning the utility of PDA closure 
in premature infants may have influenced these opinions [16, 22].
In 2010, William Benitz performed a meta-analysis of 49 RCTs involving nearly 
5000 preterm infants who underwent pharmacological or surgical treatment to close 
the PDA [16]. Evidence showed that while treatment was effective in achieving ductal 
closure, only a single study showed improvement in other outcomes such as pulmo-
nary hemorrhage, BPD, NEC, or death. Correlations between PDA and IVH were 
and did not support the hypothesis that closure of the ductus improves neurological 
outcomes [16–22]. It was concluded that the association of comorbidities with PDA 
might arise from prematurity itself rather than through prolonged patency of the 
ductus. Benitz recommended prolonging treatment of the PDA in infants ≤1000 g 
until the second week after birth to increase the odds of spontaneous closure, and 
refraining from all treatment specifically intended to close the ductus in infants 
>1000 g. Fluid restriction, diuretics, supplemental oxygen, and other treatments were 
recommended in lieu of COX inhibitors and surgical ligation [16]. Certain patients 
at special risk for complications related to PDA would still require ductal closure and 
should be identified via a scoring system, such as the one proposed by McNamara and 
Sehgal [21]. Benitz’s study provided impetus for the trend against early routine treat-
ment of the PDA in premature infants and towards a more selective approach wherein 
only certain infants at increased risk received intervention to close the ductus.
In 2018, Ronald Clyman designed the PDA Tolerate Trial [13] to further examine 
early routine therapy versus conservative management by controlling for variables 
that had confounded many of the previous RCTs. Inclusion criteria was limited to 
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infants with a moderate-to-large PDA that did not close spontaneously within the 
first week. In so doing, the number of infants who spontaneously closed the ductus 
was reduced, though not eliminated. Early routine therapy (ERT) with pharmaco-
logical treatment was then compared to conservative management. As in previous 
trials, ERT did not always result in constriction of the ductus. Results indicated that 
ERT did not improve the incidence of NEC, IVH, BPD or death but instead delayed 
full feeding and may have increased the rate of sepsis and death in infants between 
26 and 28 weeks gestation. Again, evidence did not support broad, routine ductal 
closure by pharmacotherapeutics in preterm infants.
With evidence mounting against the use of COX inhibitors and surgical ligation, 
the trend towards permissive conservative observation of this lesion has developed, 
reserving surgery for only the most severe cases [13–17, 32]. Unfortunately, recent 
data suggests that this approach is associated with an increased risk for the develop-
ment of chronic lung disease and death, especially in infants born ≤26 weeks’ gesta-
tion [8–17]. More recently in the United States, survival of infants born as early as 
22 weeks’ gestation is now possible [33], making the need for effective PDA therapy 
in this high risk, ELBW population more important than ever.
10. Role of transcatheter PDA closure in the future
Transcatheter therapy has evolved significantly in the last decade. Emerging 
technology has paved the way for the use of this therapy in smaller and smaller 
infants [34, 35]. The Amplatzer Piccolo Occluder (Abbott Structural Heart, 
Plymouth, MN, USA) is a self-expandable, Nitinol mesh device with a central cylin-
drical waist and low-profile retention discs that are marginally larger than the waist, 
resulting in a nearly isodiametric device. The device comes pre-loaded on a delivery 
wire, which has a soft floppy distal end with a microscrew attachment at the tip. It 
is delivered through a catheter using a loading device. The APO has ideal charac-
teristics (size, shape, delivery system) for closure of PDAs in premature neonates 
including ELBW infants. With an increasing need for a less invasive therapy for 
PDA closure in this population, a clinical study evaluating the safety and efficacy of 
the APO was conducted that led to the approval of this device by the U.S. Food and 
Drug Administration (FDA) for children ≥700 g [36].
While transcatheter closure of the PDA is common among larger children and 
adults, several modifications specific for ELBW patients are necessary to ensure 
success and minimize complications.
• Transportation of ELBW infants to the catheterization lab poses challenges 
for these fragile patients, but with proper coordination of team members, 
can be accomplished without complication [37]. Special accommodations for 
temperature control and ventilator support are essential. One operator has 
thus far reported success with procedures performed at the bedside. While this 
procedure may eventually become common at the bedside, transport to the 
catheterization lab will likely be necessary in most institutions.
• Arterial access in these small patients is very likely to cause damage leading 
to limb ischemia and should be avoided [34, 38]. Instead, antegrade access 
through the femoral vein is the method of choice.
• The lack of arterial access and resulting inability to perform aortography post-
deployment necessitates the use of TTE [39] to assess aortic flow, residual PDA 
shunting, and left PA (LPA) flow (Figure 3).
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• The central waist of the APO is designed to fill the ductal lumen, and the 
retention discs are designed to deploy in the pulmonary and the aortic ends 
of the PDA. However, when treating small infants, especially those ≤2 kg, 
implantation of both retention discs completely within the duct (intra-
ductal placement) to avoid protrusion into the aorta or the LPA (Figure 4) 
is essential to avoid inadvertent stenosis of these vessels by the device discs 
[24, 34, 40].
• Minimization of contrast dosing, intracardiac catheter manipulation, and 
unnecessary hemodynamic measurements that prolong procedure time are 
recommended to achieve optimal outcomes [24, 34, 40].
Figure 3. 
TTE with color Doppler interrogation of the PDA of patient described in Figures 1 and 2 before (A) and 
after transcatheter device closure (B). The PDA is completely closed following intraductal implantation of the 
occlusion device. There is no stenosis of the left pulmonary artery (LPA) or the aorta caused by the device (B).
Figure 4. 
Angiograms performed during transcatheter device closure of the PDA of patient described in Figures 1 and 2. 
Prior to closure (A), a large PDA is demonstrated shunting left to right between the aorta and the pulmonary 
artery (PA). Following device implantation within the PDA (B), there is no residual PDA, and no stenosis of 
the PA or the aorta caused by the device.
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• Following deployment, but prior to device release, in addition to echocardio-
graphic assessment as noted above, angiography should be performed to check 
for stenosis of the proximal LPA caused by the device [39].
By observing these precautions, transcatheter therapy in ELBW infants can be 
safely performed. This new therapy could shift the paradigm of treatment. Future 
randomized trials using TCPC are necessary to determine whether PDA closure 
would impact the short term and long term outcomes of children born prematurely. 
The benefit of this therapy over other therapies must be demonstrated before it can 
become standard of care for premature infants [41, 42], but this new option may 
offer a solution to the substantial unmet need in this population for a minimally 
invasive, definitive closure of the ductus.
11. Conclusions
The role of TCPC in ELBW infants will likely grow steadily, given the potential 
benefits of TCPC over other therapies. However, the most important question 
of “whether” the PDA needs to be closed at all still has to be answered. It is also 
prudent to determine “which” patients will benefit from closure, and in whom it is 
likely to close spontaneously. An RCT comparing TCPC vs. observation/conserva-
tive approach may be important to answer these questions. Hopefully, in the near 
future we will establish a treatment algorithm for ELBW with hsPDA.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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